Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016

Eurosurveillance

Volumn 21, Issue 47, 2016, Pages

  Weil, Merav ^a   Shulman, L M ^a,b   Heiman, S ^c   Stauber, T ^c   Alfandari, J ^a   Weiss, L ^a   Silberstein, I ^a   Indenbaum, V ^a   Mendelson, E ^a,b   Sofer, D ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Edmond and Lily Safra Children s Hospital Sheba Medical Center   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CASE REPORT; EXCRETION; EXPOSURE; HOSPITAL; HUMAN; ISRAEL; NONHUMAN; POLIOMYELITIS VIRUS; COMPLICATION; DISEASE ERADICATION; DISEASE OUTBREAKS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; ISOLATION AND PURIFICATION; POLIOMYELITIS; VIROLOGY; VIRUS SHEDDING;

DISEASE ERADICATION; DISEASE OUTBREAKS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; ISRAEL; POLIOMYELITIS; POLIOVIRUS; VIRUS SHEDDING;

EID: 85006059521     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES.2016.21.47.3040     Document Type: Article

References (19)

1. Global Polio Eradication Initiative (GPEI). Global eradication of wild poliovirus type 2 declared. GPEI; 2015.
2. World Health Organization (WHO). World Health Assembly resolution: poliomyelitis. Geneva: WHO; 2015. Sixty-Eighth World Health Assembly, May 26, 2015. Resolution no. WHA 68.3.
3. World Health Organization (WHO). WHO Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use (GAPIII). Geneva: WHO; 2015.
4. Centers for Disease Control and Prevention (CDC). Laboratory surveillance for wild poliovirus and vaccine-derived poliovirus, 2000-2001.MMWR Morb Mortal Wkly Rep. 2002;51(17):369-71. PMID: 12018383
5. Shulman LM, Manor Y, Sofer D, Handsher R, Swartz T, Delpeyroux F, et al. Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS One. 2006;1(1):e69. DOI: 10.1371/journal.pone.0000069 PMID: 17183700
6. Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range.J Virol. 2008;82(9):4429-40. DOI: 10.1128/JVI.02354-07 PMID: 18287242
7. Sutter RW, Cochi SL, Melnick JL. Live Attenuated Poliovirus Vaccines. In: Plotkin S, Orenstein WA, editors. Vaccines, Third Edition. Philadelphia: W.B. Saunders Company; 1999. p. 364-408.
8. Li L, Ivanova O, Driss N, Tiongco-Recto M, da Silva R, Shahmahmoodi S, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J Infect Dis. 2014;210(Suppl 1):S368-72. DOI: 10.1093/infdis/jiu065 PMID: 25316857
9. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication.Annu Rev Microbiol. 2005;59(1):587-635. DOI: 10.1146/annurev.micro.58.030603.123625 PMID: 16153180
10. Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.PLoS Pathog. 2015;11(8):e1005114. DOI: 10.1371/journal.ppat.1005114 PMID: 26313548
11. Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses.J Infect Dis. 2014;210(Suppl 1):S283-93. DOI: 10.1093/infdis/jiu295 PMID: 25316847
12. Alexander JP, Ehresmann K, Seward J, Wax G, Harriman K, Fuller S, et al., Vaccine-Derived Poliovirus Investigations Group. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota.J Infect Dis. 2009;199(3):391-7. DOI: 10.1086/596052 PMID: 19090774
13. Yang CF, Chen HY, Jorba J, Sun HC, Yang SJ, Lee HC, et al. Intratypic recombination among lineages of type 1 vaccinederived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol. 2005;79(20):12623-34. DOI: 10.1128/JVI.79.20.12623-12634.2005 PMID: 16188964
14. Shulman LM, Mendelson E, Anis E, Bassal R, Gdalevich M, Hindiyeh M, et al. Laboratory challenges in response to silent introduction and sustained transmission of wild poliovirus type 1 in Israel during 2013. J Infect Dis. 2014;210(Suppl 1):S304-14. DOI: 10.1093/infdis/jiu294 PMID: 25316849
15. Dowdle WR, Gary HE, Sanders R, van Loon AM. Can posteradication laboratory containment of wild polioviruses be achieved? Bull World Health Organ. 2002;80(4):311-6.PMID: 12075368
16. Kaliner E, Kopel E, Anis E, Mendelson E, Moran-Gilad J, Shulman LM, et al. The Israeli public health response to wild poliovirus importation. Lancet Infect Dis. 2015;15(10):1236-42. DOI: 10.1016/S1473-3099(15)00064-X PMID: 26213249
17. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, et al. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. J Infect Dis. 2015;211(11):1800-12. DOI: 10.1093/infdis/jiu674 PMID: 25505296
18. Yaari R, Kaliner E, Grotto I, Katriel G, Moran-Gilad J, Sofer D, et al., POG group. Modeling the spread of polio in an IPVvaccinated population: lessons learned from the 2013 silent outbreak in southern Israel.BMC Med. 2016;14(1):95. DOI: 10.1186/s12916-016-0637-z PMID: 27334457
19. Guo J, Bolivar-Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.Vaccine. 2015;33(10):1235-42. DOI: 10.1016/j.vaccine.2015.01.018 PMID: 25600519